Modeling CNS inflammatory demyelination using myelin-directed CAR T cells

Multiple sclerosis therapies remain confined to immunomodulatory agents that reduce inflammatory activity; none restores lost myelin, and disability can continue to accumulate independently of relapses. Development of remyelinating therapies has been hindered by models that incompletely reproduce the persistently inflamed lesions in which remyelination fails. Here we show that chimeric antigen receptor (CAR) T cells targeting myelin oligodendrocyte glycoprotein (MOG) build such lesions on demand. Human CD4+ CAR T cells transferred into immunodeficient mice infiltrated the brain, spinal cord, and optic nerve, producing perivascular demyelinating lesions, with reproducible optic nerve involvement. Within these discrete optic nerve lesions, treatment with the remyelinating compound clemastine reduced lesion size and improved optic nerve conduction, despite persistent inflammation. Thus, this MOG CAR T model reproduces key features of inflammatory demyelinating disease and enables testing of remyelinating therapies; more broadly, it introduces CAR T cells as programmable perturbative agents for building defined pathology in vivo.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-18
DOI
https://doi.org/10.64898/2026.11.16.767139
Primary Topic
Multiple Sclerosis Research Studies
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Modeling CNS inflammatory demyelination using myelin-directed CAR T cells

Caroline Guglielmetti, Chanelle Shepherd, Wendell A. Lim, Ben Ng et al.
3 links
bioRxiv (Cold Spring Harbor Laboratory)
Multiple Sclerosis Research Studies
preprint

Modeling CNS inflammatory demyelination using myelin-directed CAR T cells

Caroline Guglielmetti, Chanelle Shepherd, Wendell A. Lim, Ben Ng, Ari Green, Christian Cordano, Michael R. Wilson, Sharon A. Sagan, Scott S. Zamvil, Milos Simic, Ahmed Abdelhak, Jason Duecker, Alexandra Beaudry‐Richard, Robert Zhu, Madison Heady, Sasha Gupta, Wei Yu, Jung Sin, Liana Kozanno, Stephen Hauser, Angelica Montevirgen, David Stefanoff
preprint en

Abstract

Multiple sclerosis therapies remain confined to immunomodulatory agents that reduce inflammatory activity; none restores lost myelin, and disability can continue to accumulate independently of relapses. Development of remyelinating therapies has been hindered by models that incompletely reproduce the persistently inflamed lesions in which remyelination fails. Here we show that chimeric antigen receptor (CAR) T cells targeting myelin oligodendrocyte glycoprotein (MOG) build such lesions on demand. Human CD4+ CAR T cells transferred into immunodeficient mice infiltrated the brain, spinal cord, and optic nerve, producing perivascular demyelinating lesions, with reproducible optic nerve involvement. Within these discrete optic nerve lesions, treatment with the remyelinating compound clemastine reduced lesion size and improved optic nerve conduction, despite persistent inflammation. Thus, this MOG CAR T model reproduces key features of inflammatory demyelinating disease and enables testing of remyelinating therapies; more broadly, it introduces CAR T cells as programmable perturbative agents for building defined pathology in vivo.

bioRxiv (Cold Spring Harbor Laboratory)
University of California, San Francisco (US), University of Chicago (US)
Fondazione Italiana Sclerosi Multipla, Multiple Sclerosis Society
Good health and well-being
Multiple Sclerosis Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon